Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02266147
Recruitment Status : Terminated (The sponsor terminated the trial early because there was sufficient data to make a decision about SD-101 in the lymphoma development program.)
First Posted : October 16, 2014
Results First Posted : September 4, 2020
Last Update Posted : September 4, 2020
Sponsor:
Information provided by (Responsible Party):
Dynavax Technologies Corporation

Tracking Information
First Submitted Date  ICMJE October 13, 2014
First Posted Date  ICMJE October 16, 2014
Results First Submitted Date  ICMJE June 29, 2020
Results First Posted Date  ICMJE September 4, 2020
Last Update Posted Date September 4, 2020
Study Start Date  ICMJE October 2014
Actual Primary Completion Date April 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 20, 2020)
  • Number of Participants Experiencing Dose-limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD). [ Time Frame: Up to Day 36 ]
  • Number of Participants Experiencing Injection-site Reactions (ISRs) [ Time Frame: Up to Day 36 ]
    Injection site reaction 1 = Redness, Injection site reaction 2 = Swelling, Injection site reaction 3 = Pain
  • Number of Participants Experiencing Serious Adverse Events (SAEs) [ Time Frame: Up to 38 weeks ]
  • Pharmacodynamic Profile - Expression of IFN-responsive Genes (GBP-1, ISG-54, MCP-1, and MxB) [ Time Frame: Change from Day 8 to Day 9 ]
    Fold change of IFN-responsive gene expression relative to Day 8
Original Primary Outcome Measures  ICMJE
 (submitted: October 13, 2014)
  • Number of participants experiencing dose-limiting toxicities (DLTs), injection-site reactions (ISRs), adverse events (AEs), and serious adverse events (SAEs) [ Time Frame: DLTs and ISRs evaluated through 7 days after last dose (Day 36); AEs evaluated through Day 90; SAEs evaluated for up to 2 years. ]
  • Changes in interferon (IFN)-inducible genes [ Time Frame: Evaluated through Day 9. ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 20, 2020)
  • Number of Participants With Preliminary Response - Local (Injected Lesions) [ Time Frame: Up to 38 weeks ]
    Subjects with maximum decrease of 50% or greater in sum of products of diameters of lesions.
  • Number of Participants With Preliminary Response - Systemic (Non-injected Lesions) [ Time Frame: Up to 38 weeks ]
    Subjects with maximum decrease of 50% or greater in sum of products of diameters of lesions.
Original Secondary Outcome Measures  ICMJE
 (submitted: October 13, 2014)
  • Response rate of treated tumor according to Cheson criteria [ Time Frame: Up to 2 years ]
  • Response rate of untreated tumor according to Cheson criteria [ Time Frame: Up to 2 years ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
Official Title  ICMJE A Phase 1/2, Non-randomized, Open-label, Multicenter, Dose Escalation and Expansion Study of Intratumoral Injections of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
Brief Summary To assess the safety and tolerability of escalating doses of SD-101 in combination with localized low-dose radiation therapy in adult subjects with untreated low-grade B-cell lymphoma.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE B-cell Lymphoma
Intervention  ICMJE
  • Drug: SD-101
  • Radiation: Radiation therapy
Study Arms  ICMJE Experimental: SD-101 in combination with low-dose radiation

PART 1

  • Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1
  • COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29
  • COHORT 2: 2 mg/mL at Days 1, 8, 15, 22, and 29
  • COHORT 3: 4 mg/mL at Days 1, 8, 15, 22, and 29
  • COHORT 4: 8 mg/mL at Days 1, 8, 15, 22, and 29

PART 2

Cycle 1: Required

  • Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1
  • COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29
  • COHORT 2: 8 mg/mL at Days 1, 8, 15, 22, and 29

Cycle 2: Optional

  • Radiation: 2 fractions of 2 Gy over 2 days at Days 180 and 181
  • COHORT 1: 1 mg/mL at Days 181, 188, 195, 202, and 209
  • COHORT 2: 8 mg/mL at Days 181, 188, 195, 202, and 209
Interventions:
  • Drug: SD-101
  • Radiation: Radiation therapy
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: March 2, 2017)
29
Original Estimated Enrollment  ICMJE
 (submitted: October 13, 2014)
25
Actual Study Completion Date  ICMJE April 2017
Actual Primary Completion Date April 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Biopsy confirmed, untreated, low-grade B-cell lymphoma, including follicular (Grade 1, 2, or 3A) [Harris, Swerdlow et al. 2008] or marginal, or CLL/SLL with lymph node involvement.
  • At least 2 sites of measurable disease per Cheson criteria (must measure at least 1.5 cm in any diameter or 1.0 cm in the shortest diameter if one of the diameters is not ≥ 1.5 cm), one of which must be palpable and easily accessible in a low-risk site (eg, inguinal, axillary, cervical, subcutaneous) for intratumoral injection (denoted as "Lesion A" in Treatment Cycle 1) and at least one additional untreated lesion that is located outside the radiation field of the treated lesion (Lesion A) and is accessible for an FNA aspirate.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1
  • Aged 18 years and older
  • Absolute neutrophil count (ANC) ≥ 1500/mm3
  • Platelet count > 100,000/µL
  • Serum creatinine (Cr) ≤ 1.5 x upper limit of normal (ULN).
  • Serum total bilirubin ≤ 1.5 x the ULN.
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN
  • International normalized ratio or prothrombin time (PT) ≤ 1.5 x ULN unless subject is receiving anticoagulant therapy and the PT or partial thromboplastin time (PTT) must be within the therapeutic range of the intended use of anticoagulants.
  • Activated PTT (aPTT) ≤ 1.5 x ULN unless subject is receiving anticoagulant therapy, and the PT or PTT is within therapeutic range of intended use of anticoagulants.
  • Female subjects must have a negative urine or serum pregnancy test within 72 hours prior to taking study medication if of childbearing potential as defined in this protocol. Women of childbearing potential (WOCBP) must be willing to use 2 medically acceptable method of contraceptive from Day 1 through 120 days after the last dose of trial treatment. The 2 medically acceptable birth control methods can be either 2 barrier methods or a barrier method plus a hormonal method to prevent pregnancy. The following are considered adequate barrier methods of contraception: diaphragm, condom (by the partner), cooper intrauterine device, sponge, or spermicide as per local regulations or guidelines. Appropriate hormonal contraceptives will include any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent (including oral, subcutaneous, intrauterine, or intramuscular agents).
  • Ability to understand and sign informed consent form (ICF) and comply with treatment protocol

Exclusion Criteria:

  • Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy (including immune modulators or systemic corticosteroids) within 7 days prior to study enrollment.
  • Positive for hepatitis B (HBsAg reactive), HCV ribonucleic acid (RNA) qualitative, or human immunodeficiency virus (HIV)( HIV 1/2 antibodies)
  • Diagnosis of mantle or diffuse large-cell lymphoma, Grade 3B follicular lymphoma [Harris, Swerdlow et al. 2008] or gastric mucosa-associated lymphoid tissue (MALT) lymphoma
  • Clinically significant pleural effusion
  • Active infection including cytomegalovirus
  • Pregnant or breast feeding within the projected duration of trial participation through 4 months after the last dose of study treatment.
  • Autoimmune disease including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjӧgren's syndrome, autoimmune thrombocytopenia, history of uveitis, or other if clinically significant
  • Lymphoma involvement of the central nervous system
  • Received any prior therapy for lymphoma
  • Use of any investigational agent within the last 28 days
  • Serious, non-healing wound, ulcer, or bone fracture.
  • If a subject received major surgery, must have recovered adequately from the toxicity and/or complications from the intervention prior to enrollment.
  • Clinically significant cardiovascular disease (eg, uncontrolled hypertension, myocardial infarction, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication within 1 year prior to Day -1 (Visit 1); Grade II or greater peripheral vascular disease at study entry
  • Any other significant medical or psychiatric condition, laboratory abnormality, or difficulty complying with protocol requirements that may increase the risk associated with study participation or study drug administration that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for this study
  • History of sensitivity to any component of SD-101
  • A diagnosis of cancer within the last 3 years prior to enrollment or any known additional malignancy that is progressing or requires active treatment. Exceptions are B-cell lymphoma, basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, and in situ cervical cancer.
  • Is taking systemic corticosteroids (more than 3 consecutive days) or other immunomodulators or immune suppressive medication
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02266147
Other Study ID Numbers  ICMJE DV3-LYM-01
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Dynavax Technologies Corporation
Study Sponsor  ICMJE Dynavax Technologies Corporation
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Abraham Leung, MD Dynavax Technologies Corporation
PRS Account Dynavax Technologies Corporation
Verification Date August 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP